The global nucleic acid therapeutics market is on the brink of a major transformation. Valued at US$ 8.8 Bn in 2024, it is forecast to grow at a remarkable CAGR of 14.7%, reaching US$ 44.5 Bn by 2035. This surge reflects the rising global burden of genetic disorders, accelerating advancements in biotechnology, and a more favorable regulatory environment supporting innovation in gene-targeted...